文献速递头颈与中枢神经肿瘤

CC-486(口服阿扎胞苷)治疗经治局部晚期或转移性鼻咽癌的II期研究

Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma.
PubMed 文献 · Eur J Cancer · 2019-11-04

本研究为II期研究,评估CC-486(口服阿扎胞苷)在经1-2线治疗的局部晚期或转移性鼻咽癌患者中的疗效与安全性。36例患者入组,可评估疗效的25例中客观缓解率为12%,中位无进展生存期4.7个月,中位总生存期18.0个月。研究未进入第二阶段,结论认为CC-486单药活性不足以支持进一步开发。

要点

  • CC-486在经治晚期鼻咽癌中客观缓解率仅12%,未达到进入第二阶段所需的有效性阈值。
  • 中位无进展生存期4.7个月,中位总生存期18.0个月。
  • 常见III/IV级不良事件为中性粒细胞减少(33%)和发热性中性粒细胞减少(11%)。

核心结论

  • CC-486单药在经治局部晚期或转移性鼻咽癌中未显示足够临床活性,不支持进一步开发。
  • CC-486在鼻咽癌中的安全性特征与其他实体瘤一致。

研究设计与样本

  • II期研究,入组局部晚期或转移性鼻咽癌且既往接受1-2线治疗的患者。
  • CC-486 300 mg每日一次,21天周期中第1-14天给药,直至疾病进展或不可耐受毒性。
  • 前6例亚太岛民(API)患者以200 mg剂量起始以评估安全性,若耐受良好则后续API患者接受300 mg。
  • 若超过4例患者达到缓解,研究可进入第二阶段。
  • 共入组36例患者,中位年龄54.0岁,男性占81%,ECOG评分≤1者占97%。

主要发现

  • 在25例可评估疗效的患者中,客观缓解率为12%。
  • 中位无进展生存期为4.7个月,中位总生存期为18.0个月。
  • 最常见III/IV级治疗中出现的不良事件为中性粒细胞减少(33%)和发热性中性粒细胞减少(11%)。
  • 发生21例治疗后死亡,主要因疾病进展或疾病并发症;1例治疗中死亡(鼻出血,与研究药物无关)。
  • 研究未进入第二阶段。

关键数值与推荐

  • 共同主要终点为客观缓解率(ORR)和无进展生存期(独立评审)。
  • 关键次要终点为总生存期和安全性。
  • 研究进入第二阶段的条件为超过4例患者达到缓解。

临床怎么用

  • CC-486单药不作为经治晚期鼻咽癌的推荐治疗选择。
  • 临床决策时应关注其有限的客观缓解率和中性粒细胞减少等血液学毒性。

局限性

  • 研究因入组快于预期而提前关闭,未进入第二阶段,样本量有限。
  • 疗效可评估患者仅25例,结果解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment options are limited for recurrent nasopharyngeal carcinoma (NPC). We report results from a phase II study of CC-486 (oral azacitidine) in advanced NPC. PATIENTS AND METHODS: Patients with locally advanced or metastatic NPC and 1-2 prior treatment regimens received CC-486 300 mg daily on days 1-14 of 21-day cycles until disease progression or unacceptable toxicity. The first 6 patients of Asian-Pacific Islander (API) ethnicity received a reduced dose of 200 mg to preserve safety and tolerability; if well tolerated, subsequent API patients received CC-486 300 mg. The study could advance to stage 2 if > 4 patients achieved a response. Co-primary end-points were overall response rate (ORR) and progression-free survival (independent review). Key secondary end-points were overall survival and safety. RESULTS: Owing to faster-than-anticipated enrolment, 36 patients, including 13 of API ethnicity, were enrolled; the median age was 54.0 years. Most patients were male (81%) and had an Eastern Cooperative Oncology Group performance status ≤ 1 (97%). Among 25 efficacy-evaluable patients, the ORR was 12%; the median progression-free and overall survival were 4.7 and 18.0 months, respectively. The most common grade III/IV treatment-emergent adverse events were neutropenia (33%) and febrile neutropenia (11%). Twenty-one posttreatment deaths, primarily due to progressive disease or disease complications, and 1 on-treatment death (epistaxis, unrelated to study drug) occurred. The study did not advance to stage 2. CONCLUSION: CC-486 did not show sufficient clinical activity to support further development as monotherapy in this patient population. The safety profile of CC-486 in NPC was consistent with that in other solid tumours.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mesia R, Bossi P, Hansen AR, et al. Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. Eur J Cancer. 2019. PMID: 31698327. doi:10.1016/j.ejca.2019.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。